key: cord-1044847-zr66cnlo
authors: Kosiborod, Mikhail N; Esterline, Russell; Oscarsson, Jan; Gasparyan, Samvel B; Furtado, Remo H M; Verma, Subodh; Berwanger, Otavio
title: Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply
date: 2021-12-15
journal: Lancet Diabetes Endocrinol
DOI: 10.1016/s2213-8587(21)00326-0
sha: 10aeee82c5a689982311cc34d5f64b433af4f60e
doc_id: 1044847
cord_uid: zr66cnlo

nan

We appreciate the correspondence from Thiago Reis and colleagues regarding the selection of criteria for acute kidney injury in the DARE-19 trial. 1 We used several definitions of kidney events in the trial, which were prespecified in the protocol approved by regulatory authorities in each participating country. The kidney organ dysfunction component of the primary efficacy endpoint of prevention included doubling of serum creatinine or initiation of renal replacement therapy during index hospitalisation; the first key secondary efficacy endpoint was a kidney composite, which also included serious adverse events of acute kidney injury after discharge and all-cause mortality until day 30; and acute kidney injury was also a key safety event (defined as doubling of serum creatinine during index hospitalisation or a serious adverse event of acute kidney injury after discharge until day 30). Regardless of the definitions used, there was no evidence for an increased risk of acute kidney injury with dapagliflozin compared with placebo. The number of kidney events was numerically lower in patients who received dapagliflozin across all these endpoints, although these findings did not reach statistical significance.

Reis and colleagues suggest that the definitions of acute kidney injury in the DARE-19 trial (which capture Kidney Disease: Improving Global Outcomes [KIDIGO] stage 2 and higher) were overly strict, and that all stages of acute kidney injury (including stage 1 acute kidney injury) should be used in the evaluation of SGLT2 inhibitors (which might cause an acute dip in estimated glomerular filtration rate) in patients hospitalised with acute COVID-19. The key argument behind this suggestion is that earlier stages of acute kidney injury are common, and have been shown to be of prognostic importance, but might have been missed because of our more restrictive definitions. We would like to point out that the prognostic implications of acute kidney injury referenced by Reis and colleagues typically refer to the incidence of hard clinical events, such as initiation of renal replacement therapy and death. The study by Chan and colleagues, 2 cited by Reis and colleagues, is a large study of acute kidney injury in patients hospitalised with COVID-19. Chan and colleagues, 3 specifically used the outcome of allcause mortality when referring to the prognostic implications of different acute kidney injury stages. In the DARE-19 trial, 1 we observed no signal for a higher risk of renal replacement therapy, other prespecified events of organ failure, or death in patients who received dapagliflozin; and the number of these events, although not statistically different, were numerically lower in the dapagliflozin group compared with the placebo group. Thus, although inclusion of stage 1 acute kidney injury would have likely increased the number of acute kidney injury events by adding mild elevations in serum creatinine, it would have had no effect on the results of the DARE-19 trial as it pertains to the important clinical events.

In summary, we do not believe that inclusion of KIDIGO stage 1 acute kidney injury would have altered the key conclusions of the DARE-19 trial.

MNK has received a research grant for the conduct of this study from AstraZeneca. He has also received grant and research support from AstraZeneca. He has received a grant and honoraria from Boehringer-Ingelheim, and honoraria from Sanofi,

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

AKI in hospitalized patients with COVID-19

Amgen, Novo Nordisk, Merck (Diabetes), Janssen, Bayer, Novartis, Eli Lilly, and Vifor Pharma outside the submitted work. RE, JO, and SBG are employees and stockholders of AstraZeneca. RHMF reports research grants and personal fees from AstraZeneca, Bayer, and Servier; and research grants from Pfizer, EMS, Aché, Brazilian Ministry of Health, University Health Network, and Lemann Foundation Research Fellowship. SV reports receiving grants, speaker honoraria and consulting fees from Boehringer-Ingelheim, AstraZeneca, and Janssen. He has received speaker honoraria and consulting fees from Eli Lilly, and speaker honoraria from EOCI Pharmacomm, Sun Pharmaceuticals, and Toronto Knowledge Translation Working Group during the conduct of this study. He has also received grants and consulting fees from Amgen; grants, speaker honoraria and consulting fees from Bayer, and from Merck; grants from Bristol-Myers Squibb; speaker honoraria and consulting fees from HLS Therapeutics, Novo Nordisk, and Sanofi; and speaker honoraria from Novartis. OB reports grants from AstraZeneca, Novartis, Bayer, Amgen, and Boehringer-Ingelheim.